Iovance Biotherapeutics CEO On TIL Immunotherapy For Solid Tumors

 
• By Sten Stovall

2018 will be a big year for the clinical stage biotechnology company, which is banking on progressing novel tumor infiltrating lymphocytes for the treatment of solid tumors.

Laboratory
Iovance Is Developing Transformative Tumor-Infiltrating Lymphocyte (TIL) Therapies • Source: Shutterstock

More from Strategy

More from Business